| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 169,600 | 139,850 | 94,970 | 54,070 | 41,690 |
| Sales Growth | +21.27% | +47.26% | +75.64% | +29.70% | unch |
| Net Income | -31,600 | -12,850 | -38,340 | -6,780 | -17,880 |
| Net Income Growth | -145.91% | +66.48% | -465.49% | +62.08% | unch |
Olink Holding Ab [Publ] ADR (OLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Olink Holding AB provides a platform of products and services which are deployed across major biopharmaceutical companies and clinical and academic institutions to deepen the understanding of real-time human biology. It operates principally in Europe, North America and Asia. Olink Holding AB is headquartered in Uppsala, Sweden.
Fiscal Year End Date: 12/31